37337289|t|Update on the pathological roles of prostaglandin E2 in neurodegeneration in amyotrophic lateral sclerosis.
37337289|a|Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by selective degeneration of upper and lower motor neurons. The pathogenesis of ALS remains largely unknown; however, inflammation of the spinal cord is a focus of ALS research and an important pathogenic process in ALS. Prostaglandin E2 (PGE2) is a major lipid mediator generated by the arachidonic-acid cascade and is abundant at inflammatory sites. PGE2 levels are increased in the postmortem spinal cords of ALS patients and in ALS model mice. Beneficial therapeutic effects have been obtained in ALS model mice using cyclooxygenase-2 inhibitors to inhibit the biosynthesis of PGE2, but the usefulness of this inhibitor has not yet been proven in clinical trials. In this review, we present current evidence on the involvement of PGE2 in the progression of ALS and discuss the potential of microsomal prostaglandin E synthase (mPGES) and the prostaglandin receptor E-prostanoid (EP) 2 as therapeutic targets for ALS. Signaling pathways involving prostaglandin receptors mediate toxic effects in the central nervous system. In some situations, however, the receptors mediate neuroprotective effects. Our recent studies demonstrated that levels of mPGES-1, which catalyzes the final step of PGE2 biosynthesis, are increased at the early-symptomatic stage in the spinal cords of transgenic ALS model mice carrying the G93A variant of superoxide dismutase-1. In addition, in an experimental motor-neuron model used in studies of ALS, PGE2 induces the production of reactive oxygen species and subsequent caspase-3-dependent cytotoxicity through activation of the EP2 receptor. Moreover, this PGE2-induced EP2 up-regulation in motor neurons plays a role in the death of motor neurons in ALS model mice. Further understanding of the pathophysiological role of PGE2 in neurodegeneration may provide new insights to guide the development of novel therapies for ALS.
37337289	36	52	prostaglandin E2	Chemical	MESH:D015232
37337289	56	73	neurodegeneration	Disease	MESH:D019636
37337289	77	106	amyotrophic lateral sclerosis	Disease	MESH:D000690
37337289	108	137	Amyotrophic lateral sclerosis	Disease	MESH:D000690
37337289	139	142	ALS	Disease	MESH:D000690
37337289	161	186	neurodegenerative disease	Disease	MESH:D019636
37337289	281	284	ALS	Disease	MESH:D000690
37337289	319	331	inflammation	Disease	MESH:D007249
37337289	346	350	cord	Disease	MESH:D013118
37337289	365	368	ALS	Disease	MESH:D000690
37337289	417	420	ALS	Disease	MESH:D000690
37337289	422	438	Prostaglandin E2	Chemical	MESH:D015232
37337289	440	444	PGE2	Chemical	MESH:D015232
37337289	457	462	lipid	Chemical	MESH:D008055
37337289	489	505	arachidonic-acid	Chemical	MESH:D016718
37337289	533	545	inflammatory	Disease	MESH:D007249
37337289	553	557	PGE2	Chemical	MESH:D015232
37337289	613	616	ALS	Disease	MESH:D000690
37337289	617	625	patients	Species	9606
37337289	633	636	ALS	Disease	MESH:D000690
37337289	643	647	mice	Species	10090
37337289	702	705	ALS	Disease	MESH:D000690
37337289	712	716	mice	Species	10090
37337289	782	786	PGE2	Chemical	MESH:D015232
37337289	935	939	PGE2	Chemical	MESH:D015232
37337289	962	965	ALS	Disease	MESH:D000690
37337289	1006	1030	prostaglandin E synthase	Gene	64292
37337289	1032	1037	mPGES	Gene	64292
37337289	1117	1120	ALS	Disease	MESH:D000690
37337289	1351	1358	mPGES-1	Gene	64292
37337289	1394	1398	PGE2	Chemical	MESH:D015232
37337289	1492	1495	ALS	Disease	MESH:D000690
37337289	1502	1506	mice	Species	10090
37337289	1520	1524	G93A	DNAMutation	tmVar:c|SUB|G|93|A;HGVS:c.93G>A;VariantGroup:0;OriginalGene:64292;CorrespondingGene:9536;CorrespondingSpecies:10090
37337289	1630	1633	ALS	Disease	MESH:D000690
37337289	1635	1639	PGE2	Chemical	MESH:D015232
37337289	1666	1689	reactive oxygen species	Chemical	MESH:D017382
37337289	1705	1714	caspase-3	Gene	12367
37337289	1725	1737	cytotoxicity	Disease	MESH:D064420
37337289	1764	1776	EP2 receptor	Gene	19217
37337289	1793	1797	PGE2	Chemical	MESH:D015232
37337289	1806	1809	EP2	Gene	19217
37337289	1887	1890	ALS	Disease	MESH:D000690
37337289	1897	1901	mice	Species	10090
37337289	1959	1963	PGE2	Chemical	MESH:D015232
37337289	1967	1984	neurodegeneration	Disease	MESH:D019636
37337289	2058	2061	ALS	Disease	MESH:D000690
37337289	Positive_Correlation	MESH:D015232	12367
37337289	Association	MESH:D015232	64292
37337289	Positive_Correlation	MESH:D015232	MESH:D064420
37337289	Association	MESH:D064420	19217
37337289	Positive_Correlation	MESH:D015232	MESH:D017382
37337289	Association	MESH:D000690	64292
37337289	Association	MESH:D000690	19217
37337289	Positive_Correlation	MESH:D015232	19217
37337289	Association	MESH:D015232	MESH:D007249
37337289	Association	MESH:D000690	12367
37337289	Positive_Correlation	MESH:D015232	MESH:D000690
37337289	Association	MESH:D064420	12367
37337289	Association	12367	19217
37337289	Association	MESH:D015232	MESH:D019636

